- Investigational, novel eye drop candidate was assigned PDUFA goal date of October 22, 2023 PONTE VEDRA, Fla., Feb. 21, 2023 /PRNewswire/ -- Orasis Pharmaceuticals, an emerging ophthalmic ...

Spectrum Pharmaceuticals Inc. celebrated a long-awaited win with the U.S. FDA’s approval late Sept. 9 of novel G-CSF drug eflapegrastim, cleared for use in chemotherapy-induced neutropenia nearly four ...

An Ono Pharma drug for a type of tumor affecting tissues of the joints is now FDA approved, giving the Japanese company a product with dosing and safety advantages over the Daiichi Sankyo product that ...